COST Action CA20121
Non-communicable diseases (NCDs) account for 77% of all deaths in Europe and remain the most prevalent and without effective therapy. Networking among multidisciplinary teams that explore disease from a perspective of causative pathomechanisms rather than clinical symptoms is the most appropriate approach to overcome this problem.
The transcription factor NRF2 is a master regulator of multiple cytoprotective responses and a key molecular link among many NCDs. It provides a unique strategy for drug development and repurposing that is now starting to be translated to the pharmacological and clinical arena.
The main aim and objective of the Action CA20121 is to share basic, pharmacological, and clinical knowledge about transcription factor NRF2, master regulator of multiple cytoprotective functions, and to integrate it into the stream of EU social, clinical and economic sectors with capacity to translate this knowledge into innovative therapeutics for several non-communicable diseases.
The main aim and objective of the Action CA20121 is to share basic, pharmacological, and clinical knowledge about transcription factor NRF2, master regulator of multiple cytoprotective functions, and to integrate it into the stream of EU social, clinical and economic sectors with capacity to translate this knowledge into innovative therapeutics for several non-communicable diseases.
COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.
Grant Holder: Universidad Autónoma de Madrid
Start of Action: 19 October, 2021
End of Action: 18 October, 2025
CSO approval date: 25 May 2021
Action email: info@benbedphar.org
© 2022 BenBedPhar | Design by Tuinbit Group
